Tenalisib
Sign in to save this workspacePrimary targets: PI3K · FDA status: FDA Phase I Trials Completed
Selectivity scorecard
KISS
97.98
Gini
0.702
CATDS
0.027
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Tenalisib. Strongest target: RET at 98.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 98.5% | 1.5% |
| 2 | TRKC | 98.1% | 1.9% |
| 3 | FGFR3 | 98.0% | 2.0% |
| 4 | JAK1 | 96.4% | 3.6% |
| 5 | FGFR2 | 96.0% | 4.0% |
| 6 | TRKB | 95.3% | 4.7% |
| 7 | JAK2 | 93.8% | 6.2% |
| 8 | FGFR1 | 93.2% | 6.8% |
| 9 | ROS_ROS1 | 87.4% | 12.6% |
| 10 | FGFR4 | 83.9% | 16.1% |
| 11 | FLT3 | 76.8% | 23.2% |
| 12 | DDR1 | 73.4% | 26.6% |
| 13 | TRKA | 59.0% | 41.0% |
| 14 | JAK3 | 55.1% | 44.9% |
| 15 | LIMK1 | 54.4% | 45.6% |
| 16 | TYK2 | 52.3% | 47.7% |
| 17 | MLK3_MAP3K11 | 52.0% | 48.0% |
| 18 | FLT4_VEGFR3 | 48.7% | 51.3% |
| 19 | ALK | 45.2% | 54.8% |
| 20 | C_SRC | 39.0% | 61.0% |
Selectivity landscape
Where Tenalisib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Tenalisib.
Atlas insights for Tenalisib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.834 |
| SRR23303752 | — | 0.824 |
| SRR10899984 | — | 0.823 |
| TCGA-FD-A43X-01A-11R-A23W-07 | — | 0.818 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.814 |
Annotations
Sign in to read and post annotations.
Loading…